Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag Ord (OP:BAYZF)

30.33 +0.33 (+1.11%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bayer Ag Ord

< Previous 1 2 3 Next >
Bayer Shares Fall 7% As US Court Reconsiders Monsanto PCB Exposure Case
German life sciences giant Bayer saw its shares drop by over 7% on Wednesday following a US court’s decision to review a case against Monsanto, a subsidiary acquired by Bayer in 2018. 
Via Talk Markets
Futures Rally Fizzles As Dollar, Yields And Oil Slump
US equity futures erased earlier gains and were trading with modest losses as the dollar, oil, and yields all slumped entering the US session. 
Via Talk Markets
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. 
Via Benzinga
Topics Lawsuit
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. 
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. 
Via Benzinga
Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... 
Via Benzinga
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... 
Via Benzinga
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
Via Benzinga
Topics Bankruptcy Lawsuit
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. 
Via Benzinga
What's Going On With BridgeBio Pharma Stock On Monday?
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer. 
Via Benzinga
Topics Lawsuit
Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages. 
Via Benzinga
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)  
Via Benzinga
Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's. 
Via Benzinga
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin... 
Via Benzinga
Topics Lawsuit
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... 
Via Benzinga
Topics Climate Change
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts  
Via Benzinga
Topics Lawsuit
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... 
Via Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
Via Benzinga
Topics Lawsuit
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced  
Via Benzinga
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.